NIH Public Access Author Manuscript Ann Rheum Dis. Author manuscript; available in PMC 2011 July 19.
|
|
- Julian Warner
- 6 years ago
- Views:
Transcription
1 NIH Public Access Author Manuscript Published in final edited form as: Ann Rheum Dis January ; 68(1): doi: /ard Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis PA Merkel 1, DD Cuthbertson 2, B Hellmich 3, GS Hoffman 4, DRW Jayne 5, CGM Kallenberg 6, JP Krischer 2, R Luqmani 7, AD Mahr 8, EL Matteson 9, U Specks 9, and JH Stone 10 for the Vasculitis Clinical Research Consortium 1 Boston University School of Medicine, Boston, Massachussets, USA 2 University of South Florida, Tampa, Florida, USA 3 Kreiskrankenhaus Plochingen, Plochingen, Germany 4 Cleveland Clinic, Cleveland, Ohio, USA 5 Addenbrookes Hospital, Cambridge, UK 6 University Medical Center Groningen, University of Groningen, Groningen, The Netherlands 7 University of Oxford, Oxford, UK 8 Hospital Cochin, Paris, France 9 Mayo Clinic, Rochester, Minnesota, USA 10 Massachusetts General Hospital, Boston, Massachussets, USA Abstract Aim Currently, several different instruments are used to measure disease activity and extent in clinical trials of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, leading to division among investigative groups and difficulty comparing study results. An exercise comparing six different vasculitis instruments was performed. Methods A total of 10 experienced vasculitis investigators from 5 countries scored 20 cases in the literature of Wegener granulomatosis or microscopic polyangiitis using 6 disease assessment tools: the Birmingham Vasculitis Activity Score (BVAS), The BVAS for Wegener granulomatosis (BVAS/WG), BVAS 2003, a Physician Global Assessment (PGA), the Disease Extent Index (DEI) and the Five Factor Score (FFS). Five cases were rescored by all raters. Results Reliability of the measures was extremely high (intraclass correlations for the six measures all=0.98). Within each instrument, there were no significant differences or outliers among the scores from the 10 investigators. Test/retest reliability was high for each measure: range=0.77 to The scores of the five acute activity measures correlated extremely well with one another. Conclusions Currently available tools for measuring disease extent and activity in ANCAassociated vasculitis are highly correlated and reliable. These results provide investigators with confidence to compare different clinical trial data and helps form common ground as international research groups develop new, improved and universally accepted vasculitis disease assessment instruments. Wegener granulomatosis (WG) and microscopic polyangiitis (MPA) are forms of small medium vessel vasculitis that are commonly associated with positive tests for anti-neutrophil cytoplasmic autoantibodies (ANCA) and both diseases have overlapping clinical and pathological manifestations. 12 These diseases are complex, multisystem processes that usually threaten vital organs and are associated with substantial morbidity and increased mortality. 3 The similarities of these two diseases regarding clinical presentation and Correspondence to: P A Merkel, Vasculitis Center, E5, Boston University School of Medicine, 72 East Concord Street, Boston, Massachussets, 02118, USA; pmerkel@bu.edu. Competing interests: None declared.
2 Merkel et al. Page 2 METHODS Study overview Participants Cases Assessment tools treatment regimens has led to their being commonly studied together in clinical therapeutic trials and routinely being classified as ANCA-associated vasculitides (AAV), despite the lack of perfect accuracy of this label. Assessment of disease activity in AAV is a significant challenge. There are currently several different instruments used to measure disease activity and extent in clinical trials of AAV. 4 Some measures aim to quantify disease activity, others aim to predict long-term outcome and some aim to do both. Most of these measures are derived from the original Birmingham Vasculitis Activity Score (BVAS) 56 and attempt to catalogue organ system involvement in similar fashions. Although similar in many ways, the three BVAS tools differ in several important respects, including item selection, method of attribution, weighting and application, 4 making comparison of cohorts and data difficult, leading to divisions among investigative groups, and resulting in difficulty comparing study results We performed an exercise comparing six different instruments in terms of reliability, correlation of disease activity scores, ease of use, and other features. This study is part of an effort to develop a new international consensus and data-driven vasculitis disease assessment tools. Multiple investigators scored the same set of 20 case summaries in the literature using 6 different vasculitis disease assessment instruments; 5 cases were scored twice by each rater. Results were compared across instruments and among investigators. The study was conducted by the Vasculitis Clinical Research Consortium (VCRC). The study personnel include 10 experienced vasculitis investigators from 4 countries in the EU and the USA (5 countries total) and the group included specialists from internal medicine, rheumatology, nephrology and pulmonology. A total of 20 case summaries were written in a standardised fashion by 4 different investigators based on actual patients with WG or MPA evaluated in their respective internal medicine, rheumatology, nephrology and pulmonology clinics. Six different disease assessment tools were completed by each investigator for each case. The activity measures used were: The BVAS. 5 The weighted total score was used for analysis. The BVAS for Wegener granulomatosis (BVAS/WG). 6 The weighted total score was used for analysis. The BVAS The weighted total score was used for analysis. The Physician Global Assessment (PGA) that is included in BVAS/WG. 6 This PGA is a visual analogue scale (VAS). The Disease Extent Index (DEI). 11 The total score was used for analysis. The disease prognosis tool used was the Five Factor Score (FFS), 12 (modified to allow for scoring a patient whose disease is already established). The total FFS score was used for analysis.
3 Merkel et al. Page 3 Data collection Data analysis RESULTS For each instrument all investigators reviewed a manual of operations and an item glossary. Each investigator completed a training exercise that included scoring three cases with all six instruments and reviewed annotated scoring explanations. Copies of all material are available on the VCRC website ( Each investigator scored all 20 cases with all instruments. The case order was randomised for each investigator. Order of instruments scored was the same for all investigators. Each investigator rescored five of the cases using all instruments 1 2 weeks after the initial exercise without reference to prior scoring. Inter-rater and intrarater reliabilities were measured using intraclass correlations (ICC) fixed between observer pairs. General linear models were used to test for differences between reviewers. Correlations were measured using Pearson method. All analyses were based on a two-sided significance level of 0.5. Data analysis was conducted using the SAS system(cary, North Carolina, USA). Reliability of vasculitis disease assessment instruments Inter-rater reliability of the measures was extremely high for all six measures (ICC=0.98; table 1). Within each instrument, there were no significant differences or outliers among the scores from the 10 investigators. Intrarater (test/retest) reliability was also high for each of the measures, with ICCs ranging from (table 1). Correlations among vasculitis disease assessment instruments Table 2 and fig 1 list and depict the correlations among the various disease assessment instruments. The scores of the five acute activity measures (BVAS, BVAS/WG, PGA, BVAS 2003, DEI) were highly correlated with one another. As expected, the correlations between FFS (prognostic score) and other measures were poor. Operational characteristics of the disease activity measures DISCUSSION Following the data collection phase of the exercise, investigators held scheduled freeform discussions regarding the various instruments studied. All investigators agreed that each of the tools were easy to learn and use. Assessing disease activity in vasculitis involves several major challenges including recognising that vasculitis: (a) affects multiple organ systems; (b) produces manifestations ranging from fulminant and acute disease to chronic, smouldering problems; and (c) results in tissue damage leading to chronic signs and symptoms of disease similar to, but not caused by, active disease. Furthermore, the lack of reliable biomarkers means clinician assessments remain the mainstay of activity measurement. The introduction of validated measures of disease burden in vasculitis has been instrumental in conducting clinical trials of promising new therapies, particularly for WG and MPA. 710 However, the existence of multiple instruments to measure disease activity in clinical trials of WG and MPA is divisive for the
4 Merkel et al. Page 4 vasculitis research community, is a source of confusion for the wider medical community, and complicates the comparison of results from trials using different disease measures. 4 Acknowledgments This study, comparing six different vasculitis disease assessment instruments, demonstrates that the currently available tools for measuring disease extent and activity in AAV are highly reliable and correlated. These results, therefore, give investigators more confidence that some comparisons across trials are possible. This study also demonstrates that differences among the BVAS versions may not be as great as previously perceived. Although the BVAS/WG was designed to be more disease specific, 6 it correlated highly with BVAS and BVAS 2003, at least in the one-time measures of disease activity included in this exercise. This study has several notable strengths. The investigators were highly experienced in caring for patients with vasculitis as well as participating in clinical research in these diseases. Additionally, the investigator group included representatives from multiple medical specialties and several countries. While investigators were each familiar with at least one of the instruments under study, no investigator had used all of the tools and this enhanced the study of reliability of new measures. The 20 cases used in this study were chosen to represent a wide spectrum of clinical manifestations and disease activity states. This study has some limitations to consider. First, the exercise used paper-based cases; however, the logistics and expense of having 10 investigators question and examine the same 20 patients as well as review chart material are formidable. Second, 20 cases may not represent the full spectrum of these diseases and can not include all of the manifestations an investigator might see within the context of a clinical trial. The main aim of this study, however, was to compare the instruments against one another and not to revalidate their utility in WG and MPA. The results of this study apply only to AAV and to investigators trained in the use of these instruments. The study did not attempt to rank the utility of these different measures. The results do support the idea that these measures, despite the stated goals associated with their creation, are perhaps less different than anticipated. The strong correlations between different activity measures also illustrates that even if the use of a particular instrument is not intuitive, the careful training of investigators in the use of the instrument prior to its application may result in excellent reliability. The data and insight gained from this exercise provides clinical investigators studying vasculitis with confidence to easily compare different clinical trial data in WG/MPA. This study also helps form common ground as international research groups go forward with developing new, improved and universally accepted vasculitis disease assessment instruments. Funding: Grants were received from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (UO1 AR51874) and the National Center for Research Resources/NIH: U54 RR The Vasculitis Clinical Research Consortium is part of the NIH Rare Diseases Clinical Research Network ( PAM, ELM and JHS were supported by Mid-Career Development Awards in Clinical Investigation (NIH-NIAMS: K24 AR02224, AR and AR049185). None of the funding sources for this study had any role in any aspect of conducting this research, drafting the manuscript, or the decision to publish the data.
5 Merkel et al. Page 5 REFERENCES 1. Hoffman, GS.; Gross, WL. Wegener s granulomatosis: clinical aspects. In: Hoffman, GS.; Weyand, CM., editors. Inflammatory diseases of blood vessels. New York: Marcel Dekker; p Bacon, PA.; Adu, D. Microscopic polyangiitis: clinical aspects. In: Hoffman, GS.; Weyand, CM., editors. Inflammatory diseases of blood vessels. New York: Marcel Dekker; p Seo P, Min N, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage from Wegener s granulomatosis and its treatment: prospective data from the Wegener s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005; 52: [PubMed: ] 4. Merkel PA, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, et al. Current status of outcome measures in vasculitis: focus on Wegener s granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol. 2005; 32: [PubMed: ] 5. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994; 87: [PubMed: ] 6. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener s granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum. 2001; 44: [PubMed: ] 7. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349: [PubMed: ] 8. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003; 49: [PubMed: ] 9. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener s granulomatosis. Arthritis Rheum. 1997; 40: [PubMed: ] 10. WGET Research Group. Etanercept plus standard therapy for Wegener s granulomatosis. N Engl J Med. 2005; 352: [PubMed: ] 11. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener s granulomatosis. Clin Nephrol. 2001; 55: [PubMed: ] 12. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996; 75: [PubMed: ]
6 Merkel et al. Page 6 Figure 1. Correlations among the various disease assessment instruments.
7 Merkel et al. Page 7 Table 1 Inter-rater and intrarater intraclass correlations among vasculitis disease assessment indices Disease assessment tool Inter-rater ICC (95% CI) p Value for differences among reviewers Intrarater ICC (95% CI) BVAS 0.98 (0.97 to 0.99) (0.87 to 0.99) BVAS/WG 0.98 (0.96 to 0.99) (0.34 to 0.97) BVAS/ (0.97 to 0.99) (0.43 to 0.98) PGA 0.98 (0.96 to 0.99) (0.38 to 0.97) FFS 0.98 (0.96 to 0.99) (0.39 to 0.97) DEI 0.98 (0.97 to 0.99) (0.59 to 0.98) p Value for differences within reviewers BVAS, Birmingham Vasculitis Activity Score; BVAS/WG, BVAS for Wegener Granulomatosis; DEI, Disease Extent Index; FFS, Five Factor Score; ICC, intraclass correlation; PGA, Physician Global Assessment.
8 Merkel et al. Page 8 Table 2 Pearson correlation coefficients among vasculitis disease assessment indices DEI FFS BVAS/2003 PGA BVAS/WG BVAS r=0.80 r=0.56 r=0.95 r=0.87 r=0.86 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 BVAS/WG r=0.85 r=0.39 r=0.88 r=0.80 p<0.001 p<0.001 p<0.001 p<0.001 PGA r=0.74 r=0.49 r=0.84 p<0.001 p<0.001 p<0.001 BVAS/2003 r=0.85 r=0.49 p<0.001 p<0.001 FFS r=0.33 p<0.001 BVAS, Birmingham Vasculitis Activity Score; BVAS/WG, BVAS for Wegener Granulomatosis; DEI, Disease Extent Index; FFS, Five Factor Score; PGA, Physician Global Assessment.
Current Status of Outcome Measures in Vasculitis: Focus on Wegener s Granulomatosis and Microscopic Polyangiitis. Report from OMERACT 7
OMERACT 7 Special Interest Group Current Status of Outcome Measures in Vasculitis: Focus on Wegener s Granulomatosis and Microscopic Polyangiitis. Report from OMERACT 7 PETER A. MERKEL, PHILIP SEO, PETER
More informationA Disease-Specific Activity Index for Wegener s Granulomatosis
ARTHRITIS & RHEUMATISM Vol. 44, No. 4, April 2001, pp 912 920 2001, American College of Rheumatology Published by Wiley-Liss, Inc. A Disease-Specific Activity Index for Wegener s Granulomatosis Modification
More informationRate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis
Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis M. Jung 1, L. Barra 2 1 Division of Rheumatology, Department of Medicine, University
More informationanti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid
Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus
More informationRemission in antineutrophil cytoplasmic antibody-associated systemic vasculitis
Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis C. Mukhtyar 1, B. Hellmich 2, D. Jayne 3, O. Flossmann 3, R. Luqmani 1 1 The Botnar Research Centre, Institute of Musculoskeletal
More informationClinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil
More informationDISEASE ASSESSMENT IN SYSTEMIC VASCULITIS R A Luqmani
Review article J Indian Rheumatol Assoc 2003 : 11 : 35-44 DISEASE ASSESSMENT IN SYSTEMIC VASCULITIS R A Luqmani Consultant Rheumatologist/Senior Lecturer in Rheumatology Rheumatology Department, Western
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationThe Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener s)
ARTHRITIS & RHEUMATOLOGY Vol. 66, No. 2, February 2014, pp 428 432 DOI 10.1002/art.38248 2014, American College of Rheumatology BRIEF REPORT The Value of a Patient Global Assessment of Disease Activity
More informationRituximab treatment for ANCA-associated vasculitis in childhood
Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine
More informationGlucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
Article Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and Patrick
More informationThe European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France
The European and French networks Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France French Vasculitis Study Group December 1980: L. Guillevin no research,
More informationCase Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013
Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationpresence of ANCA, older age and male gender.
1 Botnar Research Centre, University of Oxford, Oxford, UK; 2 Department of Nephrology, Addenbrooke s Hospital, Cambridge, UK; Department of Rheumatology, University Hospital of Schleswig-Holstein, Lübeck,
More informationT he primary systemic vasculitides (PSV) are clinically
605 EXTENDED REPORT EULAR recommendations for conducting clinical studies and/ or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis Bernhard Hellmich,
More informationMicroscopic polyangiitis (MPA) is a small- to medium-size
Mycophenolate Mofetil for Induction and Maintenance of Remission in Microscopic Polyangiitis with Mild to Moderate Renal Involvement A Prospective, Open-Label Pilot Trial Francisco Silva,* Ulrich Specks,*
More informationEULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis
EULAR recommendations for clinical trials in vasculitis 1 EULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis Bernhard
More informationClinical analysis of nervous system involvement in ANCA-associated systemic vasculitides
Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides W. Zhang, G. Zhou*, Q. Shi, X. Zhang, X.-F. Zeng, F.-C. Zhang Department of Rheumatology, Peking Union Medical College
More informationAntineutrophil cytoplasmic antibody (ANCA) associated. Article
Annals of Internal Medicine Article Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody Associated Small-Vessel Vasculitis Susan L. Hogan, PhD, MPH; Ronald J. Falk, MD;
More informationRelation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis
Houben et al. BMC Nephrology (2017) 18:378 DOI 10.1186/s12882-017-0797-x RESEARCH ARTICLE Open Access Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis Eline
More informationOptimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials
Prague Medical Report / Vol. 107 (2006) No. 2, p. 199 212 199) Optimizing the Therapeutic Strategies in ANCA-Associated Vasculitis Single Centre Experience with International Randomized Trials Vaňková
More informationLong-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange: a retrospective, single-centre study
Frausová et al. Arthritis Research & Therapy (2016) 18:168 DOI 10.1186/s13075-016-1055-5 RESEARCH ARTICLE Open Access Long-term outcome of patients with ANCAassociated vasculitis treated with plasma exchange:
More informationSmall-Vessel and Medium-Vessel Vasculitis
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 57, No. 8, December 15, 2007, pp 1552 1559 DOI 10.1002/art.23105 2007, American College of Rheumatology REVIEW ARTICLE Small-Vessel and Medium-Vessel
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationOptimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases
Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases C. Ponte 1,2, J. Sznajd 1,3, L. O Neill 1,4, R.A. Luqmani 1 1 Nuffield Department of Orthopaedics
More informationDisease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis
Original Article DOI 10.1002/acr.23099 Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis Zachary S. Wallace,
More informationfor the European Vasculitis Study Group submitted
Predictors of long-term ( 5 year) renal survival in 55 patients with ANCA-associated vasculitis Annelies Berden Oliver Floßmann Kerstin Westman Peter Höglund Chris Hagen Saskia le Cessie Michael Walsh
More informationGranulomatosis With Polyangiitis (Wegener s) Impact of Maintenance Therapy Duration
Granulomatosis With Polyangiitis (Wegener s) Impact of Maintenance Therapy Duration Jason Springer, MD,* Benjamin Nutter, MS, Carol A. Langford, MD, MHS, FACP, Gary S. Hoffman, MD, MS, MACR, and Alexandra
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationAnnals of the Rheumatic Diseases 2011; 70(3):
Long-term patient survival in ANCA-associated vasculitis Oliver Floßmann Annelies Berden Kirsten de Groot Chris Hagen Lorraine Harper Caroline Heijl Peter Höglund David Jayne Raashid Luqmani Alfred Mahr
More informationDamage Assessment in ANCA-Associated Vasculitis
Curr Rheumatol Rep (2012) 14:494 500 DOI 10.1007/s11926-012-0291-1 VASCULITIS (LR ESPINOZA, SECTION EDITOR) Damage Assessment in ANCA-Associated Vasculitis Kuljeet Bhamra & Raashid Luqmani Published online:
More informationNon-commercial use only
Case RepoRt Reumatismo, 2013; 65 (2): 90-94 Granulomatosis polyangiitis associated with meningeal involvement: response to rituximab therapy after failure of cyclophosphamide Corresponding author: Maurizio
More informationClinical Features of Microscopic Polyangiitis: A Cohort Study in a Southern Taiwan Medical Center
Acta Nephrologica 26(4): 198-5, 12 DOI: 1.6221/AN.1128 Original Article Clinical Features of Microscopic Polyangiitis: A Cohort Study in a Southern Taiwan Medical Center Chun-Kai Huang 1, 3, Hua-Chang
More informationConsequences of disease and treatment in ANCA-associated vasculitis Tuin, Janneke
University of Groningen Consequences of disease and treatment in ANCA-associated vasculitis Tuin, Janneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationThe systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D.
60 Treatment of ANCA-associated Systemic Vasculitis H. Michael Belmont, M.D. Abstract The antineutrophil cytoplasmic antibodies (ANCA)-associated small vessel vasculitides include Wegener s granulomatosis,
More informationCitation for published version (APA): Chen, M. (2009). Pathogenetic and clinical aspects of ANCA-associated vasculitis Groningen: s.n.
University of Groningen Pathogenetic and clinical aspects of ANCA-associated vasculitis Chen, Min IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationJ Am Soc Nephrol 10: , 1999
J Am Soc Nephrol 10: 1965 1971, 1999 Mycophenolate Mofetil for Maintenance Therapy of Wegener s Granulomatosis and Microscopic Polyangiitis: A Pilot Study in 11 Patients with Renal Involvement RAINER NOWACK,*
More informationRheumatology. Modern management of primary systemic vasculitis CME: CLINICAL PRACTICE AND ITS BASIS
CME: CLINICAL PRACTICE AND ITS BASIS Rheumatology Edited by Richard Watts DM FRCP, Consultant Rheumatologist, Ipswich Hospital NHS Trust; Senior Lecturer, School of Medicine, Health Policy, University
More informationImmunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
Clinical Kidney Journal, 2017, vol. 10, no. 4, 470 474 doi: 10.1093/ckj/sfx014 Advance Access Publication Date: 12 April 2017 Original Article ORIGINAL ARTICLE Immunoglobulin levels and infection risk
More informationAnti-neutrophil cytoplasmic antibody-associated vasculitis
12 Anti-neutrophil cytoplasmic antibody-associated vasculitis Sandeep Bawa, Chetan Mukhtyar, Raashid Luqmani Introduction Wegener s granulomatosis (WG), microscopic polyangiitis (MPA) and Churg Strauss
More informationLung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow up in ANCA associated vasculitis
Hassan et al. BMC Immunology 1, 1: http://www.biomedcentral.com/171-17/1/ RESEARCH ARTICLE Open Access involvement at presentation predicts disease activity and permanent organ damage at, 1 and months
More informationTell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
More informationOlder patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study
Manno et al. BMC Nephrology (2015) 16:88 DOI 10.1186/s12882-015-0082-9 RESEARCH ARTICLE Open Access Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective
More informationC irculating endothelial cells (CECs) are a new marker of
164 EXTENDED REPORT Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis A Woywodt, C Goldberg, T Kirsch, K de Groot, U Erdbruegger, H Haller, M
More informationElevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis
Original Article Elevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis Huijuan Wang, Chao Zhang, Zhaohui Tong, Xiaoning Bu Department
More informationA Study of Atherosclerosis in Systemic Vasculitis
Original Article A Study of Atherosclerosis in Systemic Vasculitis Silas Supragya Nelson, Sonjjay Pande, Avadhesh Pratap Singh Kushwah 3 Assistant Professor in the Department of Medicine, NSCB Medical
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationVasculitis of the peripheral nervous system
4 rd Congress of the European Academy of Neurology Lisbon, Portugal, June 16-19, 2018 Teaching Course 5 Acute emergencies in neuromuscular disease - Level 2 Vasculitis of the peripheral nervous system
More informationDiscontinuation of therapies in vasculitis
Discontinuation of therapies in vasculitis R. Luqmani National Institute of Health Research Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom. Raashid Luqmani, DM,
More informationThe role of biologics in treatment of ANCA-associated vasculitis
Mod Rheumatol (2012) 22:319 326 DOI 10.1007/s10165-011-0548-y REVIEW ARTICLE The role of biologics in treatment of ANCA-associated vasculitis Chethana Dharmapalaiah Richard A. Watts Received: 29 July 2011
More informationCitation for published version (APA): Stassen, P. M. (2008). ANCA-associated vasculitis. Triggers and treatment s.n.
University of Groningen ANCA-associated vasculitis. Triggers and treatment Stassen, Patricia Maria IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationEudraCT number: Page 8 of 42
EudraCT number: 2012-001102-14 Page 8 of 42 5 Trial Synopsis Title Sponsor name North American Sponsor Disease Under Investigation An international, open label, randomised, controlled trial comparing rituximab
More informationKidney Diseases. Systemic Vasculitis: Still a Challenging Disease. Irina Buhaescu, MD, Adrian Covic, MD, PhD, and Jeremy Levy, PhD
AJKD American REVIEWS The Official Journal of the National Kidney Foundation Journal of Kidney Diseases Systemic Vasculitis: Still a Challenging Disease Irina Buhaescu, MD, Adrian Covic, MD, PhD, and Jeremy
More informationWegener s Granulomatosis
Wegener s Granulomatosis Authors: Professor Loïc Guillevin 1,2, Doctor Alfred Mahr Creation Date: May 2002 Update: January 2004 1 CHU Hôpital Cochin, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
More informationAN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS
GRANULOMATOSIS WITH POLYANGIITIS (GPA), MICROSCOPIC POLYANGIITIS (MPA), and EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS What is ANCA-associated Vasculitis?
More informationVascularites rénales associées aux ANCA
Vascularites rénales associées aux ANCA Société Médicale des Hôpitaux de Paris 16 Mars 2012 Philippe Vanhille Néphrologie et Médecine Interne Hôpital de Valenciennes Classification of systemic vasculitis:
More informationNIH Public Access Author Manuscript N Engl J Med. Author manuscript; available in PMC 2011 July 15.
NIH Public Access Author Manuscript Published in final edited form as: N Engl J Med. 2010 July 15; 363(3): 221 232. doi:10.1056/nejmoa0909905. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
More informationANCA serology in the diagnosis and management of ANCA-associated renal vasculitis GUIDELINES
NEPHROLOGY 2008; 13, S17 S23 ANCA serology in the diagnosis and management of ANCA-associated renal vasculitis Date written: June 2007 Final submission: October 2007 Author: Grant Luxton, Robyn Langham
More informationImproved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies
Nephrol Dial Transplant (2015) 30: i67 i75 doi: 10.1093/ndt/gfv008 Advance Access publication 17 February 2015 Original Article Improved prognosis in Norwegian patients with glomerulonephritis associated
More informationPersistent hematuria in patients with. vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?
Lv et al. BMC Nephrology (2017) 18:354 DOI 10.1186/s12882-017-0763-7 RESEARCH ARTICLE Open Access Persistent hematuria in patients with antineutrophil cytoplasmic antibodyassociated vasculitis during clinical
More informationVasculitis Update 2017
June 24, 2017 Chicago, Illinois Sponsored by: Office of Continuing Medical Education Division of Rheumatology Vasculitis Clinical Research Consortium Vasculitis Foundation Page 2 About At Northwestern
More informationRituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
The new england journal of medicine original article Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis John H. Stone, M.D., M.P.H., Peter A. Merkel, M.D., M.P.H., Robert Spiera, M.D., Philip
More informationRenal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis
Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis E.S. Park, S.S. Ahn, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. Lee Division of Rheumatology, Department of Internal
More informationNew Developments in ANCA-associated Vasculitis
New Developments in ANCA-associated Vasculitis Second International Renal Conference Bruges, March 2018 Ulrich Specks, M.D. Connor Group Foundation Professor of Medicine Mayo Clinic College of Medicine
More informationAntineutrophil cytoplasm antibody associated vasculitis: recent developments
mini review http://www.kidney-international.org & 2013 International Society of Nephrology Antineutrophil cytoplasm antibody associated vasculitis: recent developments Shunsuke Furuta 1 and David R.W.
More informationA new approach to conducting randomized clinical trials in the community setting.
A new approach to conducting randomized clinical trials in the community setting. IRB # Pro00013241 The TAPIR trial is sponsored by: Vasculitis Clinical Research Consortium (VCRC) National Heart Lung and
More informationEfficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
original article Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis Ulrich Specks, M.D., Peter A. Merkel, M.D., M.P.H., Philip Seo, M.D., Robert Spiera, M.D., Carol A. Langford, M.D.,
More informationEudraCT number: Page 9 of 46
EudraCT number: 2012-001102-14 Page 9 of 46 5 Trial Synopsis Title Sponsor name North American Sponsor Japan Sponsor Ireland Sponsor Disease Under Investigation An international, open label, randomised,
More informationPlasma exchanges in ANCA-associated vasculitis
Plasma exchanges in ANCA-associated vasculitis Xavier Puéchal, MD, PhD Centre de Référence des Maladies auto-immunes systémiques rares d Ile de France Hôpital Cochin Université Paris Descartes http://www.vascularites.org
More informationThe Journal of Rheumatology Volume 42, no. 12
The Journal Volume 42, no. 12 Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody associated Vasculitis in the United States Karina Raimundo, Amanda M. Farr, Gilwan Kim and George Duna
More informationSmall Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
More informationOMERACT Endorsement of Patient-Reported Outcome Instruments in ANCA-Associated Vasculitis
OMERACT Endorsement of Patient-Reported Outcome Instruments in ANCA-Associated Vasculitis Robson JC, MRCP PhD, Consultant Senior Lecturer, University of the West of England; Honorary Senior Lecturer, University
More informationABSTRACT. n engl j med 363;3 nejm.org july 15,
The new england journal of medicine established in 1812 july 15, 21 vol. 363 no. 3 Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis Rachel B. Jones, M.R.C.P., M.D., Jan Willem Cohen
More informationSung Soo Ahn 1, Seung Min Jung 1, Jason Jungsik Song 1,2, Yong-Beom Park 1,2 and Sang-Won Lee 1,2*
Ahn et al. BMC Nephrology (2018) 19:187 https://doi.org/10.1186/s12882-018-0992-4 RESEARCH ARTICLE Open Access Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis
More informationRituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
NIHR Innovation Observatory Evidence Briefing: August 2017 Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) NIHRIO (HSRIC) ID: 12979
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationA Disease Activity Score for ENT Involvement in Granulomatosis With Polyangiitis (Wegener s)
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. A Disease Activity Score for ENT Involvement in Granulomatosis With Polyangiitis (Wegener s) Marcos Martinez
More informationDisease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia
International Journal of Clinical Rheumatology Disease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia Background: ANCA-associated vasculitis (AAV) is a potentially
More informationMaintaining remission in granulomatosis with polyangiitis (Wegener s)
Maintaining remission in granulomatosis with polyangiitis (Wegener s) Since the introduction of combined immunosuppressive therapy with oral cyclophosphamide (CYC) and glucocorticosteroids in the 1970s,
More informationCombined Infliximab and Rituximab in Necrotising Scleritis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationAssessment of disease activity in systemic. vasculitis "VUt SMu i.
Postgrad MedJ 1998;74:1-6 c The Fellowship of Postgraduate Medicine, 1998 Interfaces between medical specialties Summary The systemic vasculitides are a group of inflammatory disorders characterised by
More informationW egener s granulomatosis (WG), Churg Strauss syndrome
PAPER Peripheral neuropathy in Wegener s granulomatosis, Churg Strauss syndrome and microscopic polyangiitis Luigi Cattaneo, Elisabetta Chierici, Laura Pavone, Chiara Grasselli, Paolo Manganelli, Carlo
More informationRenal transplantation in ANCA-associated vasculitis
Renal transplantation in ANCA-associated vasculitis Mårten Segelmark Linköping University Post Print N.B.: When citing this work, cite the original article. Original Publication: Mårten Segelmark, Renal
More informationRevised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin
More informationMycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis Jones, Rachel B.
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis Jones, Rachel B.; Harper, Lorraine DOI: 10.1136/annrheumdis-2018-214245 License: Creative Commons: Attribution-NonCommercial
More informationAnti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease
Anti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease Grace M. Lee, Yara A. Park, Marshall Mazepa, Jay S. Raval Introduction Anti-neutrophil
More informationANCA-associated vasculitis with renal involvement: an outcome analysis
NDT Advance Access published April 6, Nephrol Dial Transplant () 1 of 9 DOI: 1.193/ndt/gfh161 Original Article ANCA-associated vasculitis with renal involvement: an outcome analysis Sven Weidner 1, Steffen
More informationAnti-neutrophil cytoplasmic antibody (ANCA)-associated
Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Eugene P. Rhee, Karen A. Laliberte, and John L. Niles Renal Unit, Massachusetts General Hospital, Boston,
More informationRheumatic Diseases 2005
COLLECTED REPORTS ON THE Rheumatic Diseases 2005 SERIES 4 (REVISED) Published by the Arthritis Research Campaign (arc) Editors: Ade O Adebajo FRCP(Glasgow) D John Dickson MBChB FRCP(Glasgow) FRCP(London)
More informationMicroscopic polyangiitis complicated with ileal involvement detected by double-balloon endoscopy: a case report
Fukushima et al. BMC Gastroenterology 2013, 13:42 CASE REPORT Open Access Microscopic polyangiitis complicated with ileal involvement detected by double-balloon endoscopy: a case report Masashi Fukushima
More informationProtocol Version 2.0 Synopsis
Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical
More informationEUVAS update June 5 th Marinka Twilt
EUVAS update June 5 th 2012 Marinka Twilt Chapel Hill 2012 Classification Large Vessel Vasculitis (LVV) Medium Vessel Vasculitis (MVV) Small Vessel Vasculitis (SVV) Variable Vessel Vasculitis (VVV) Single
More informationA COST EFFECTIVENESS ANALYSIS OF WEEKLY COMPLETE BLOOD COUNT MONITORING FOR LEUKOPENIA IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) ON
A COST EFFECTIVENESS ANALYSIS OF WEEKLY COMPLETE BLOOD COUNT MONITORING FOR LEUKOPENIA IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) ON CYCLOPHOSPHAMIDE By ATUL ASHOK KHASNIS, MD Submitted in
More informationTITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness
TITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness DATE: 28 January 2015 CONTEXT AND POLICY ISSUES Granulomatosis with polyangiitis
More informationEnd-stage renal disease in ANCA-associated vasculitis
Nephrol Dial Transplant (2017) 32: 248 253 doi: 10.1093/ndt/gfw046 Advance Access publication 6 April 2016 End-stage renal disease in ANCA-associated vasculitis Sergey Moiseev 1, Pavel Novikov 1, David
More informationCombination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 21 22 23 24 25 26 27 28 29 3 31 32 33 34 35 36 37 38 39 41 42 43 44 45 46 47 48 49 5 51 Combination Therapy With Rituximab and Cyclophosphamide for Remission
More information